← Back to Home

New Hope After Leukemia Remission: SELLAS Cancer Vaccine Meets Survival Endpoint in Phase 3 Trial

Galinpepimut-S shows an overall survival advantage in patients with acute myeloid leukemia who have achieved another remission but cannot undergo allogeneic stem cell transplantation; full data and regulatory review will determine whether the treatment can enter clinical practice.

By SURL BioNews

For patients with acute myeloid leukemia (AML), sustaining remission after achieving it again is often the next challenge. SELLAS Life Sciences announced on November 17 that its investigational cancer vaccine galinpepimut-S (GPS) met the primary overall survival endpoint in the Phase 3 REGAL trial, offering a new treatment lead for patients unable to undergo allogeneic hematopoietic stem cell transplantation.

According to preliminary results released by the company, median overall survival was 24.0 months in the GPS group and 14.7 months in the physician’s-choice best available treatment group, a difference of 9.3 months. The hazard ratio for death was 0.59, with a two-sided p-value of 0.035, reaching statistical significance. The company’s reported 41% reduction in the risk of death refers to the relative hazard of death during follow-up and cannot be interpreted as every patient living a fixed amount of time longer.

REGAL is a global, randomized, open-label trial in which 126 participants were assigned in a one-to-one ratio. The primary analysis was conducted according to the prespecified plan after 80 deaths had accumulated. Eligible participants had to have achieved a second or subsequent complete remission following second-line or later salvage therapy, including remission with incomplete platelet recovery, and be unsuitable for or unable to undergo allogeneic transplantation. RTTNews also confirmed these eligibility criteria in its report on the same day. The findings therefore have a clearly defined scope and cannot be directly generalized to all patients with AML.

GPS targets the tumor-associated protein WT1 and consists of four peptides derived from WT1. It is designed to prompt T cells to recognize cancer cells carrying this marker. It is a therapeutic vaccine: the study aims to use an immune response during remission to target residual leukemia cells and thereby extend survival. The trial compared GPS monotherapy as maintenance treatment with physician-selected care, which could include observation, hypomethylating agents, and other drug treatments.

Regarding safety, SELLAS said no new safety signals were identified. Treatment-related adverse events were predominantly Grade 1 or 2, with local injection reactions the most common. However, this remains a preliminary summary released by the company; full data are still needed to assess the incidence of different side effects, serious events, and treatment discontinuations.

Overall survival is a measure directly relevant to patients’ circumstances, but the current announcement is insufficient to provide a complete picture of efficacy. Secondary endpoints and other prespecified analyses are still being assessed, including immune responses and minimal residual disease. The company plans to present detailed results at a medical conference and submit them to a peer-reviewed journal. The uncertainty surrounding survival estimates, outcomes in different patient groups, and the treatments actually received by the control group will all affect subsequent interpretation.

SELLAS expects to discuss strategies for expediting its application with the U.S. Food and Drug Administration (FDA) and is targeting submission of a biologics license application in the first half of 2027; RTTNews also reported this timeline. These are the company’s plans and do not mean that the FDA has agreed to the application pathway or approved the therapy. For patients, the significance of these findings lies in the Phase 3 evidence of extended survival. Whether GPS can become an available maintenance treatment still depends on the full data and regulatory review.

References

  1. SELLAS Life Sciences via SEC
  2. SELLAS Life Sciences Group, Inc.
  3. RTTNews